West Pharmaceutical Services (NYSE:WST) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Saturday.
A number of other equities research analysts have also weighed in on WST. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Goldman Sachs assumed coverage on West Pharmaceutical Services in a research note on Wednesday, January 24th. They set a “neutral” rating and a $110.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $108.17.
Shares of WST stock opened at $83.32 on Friday. West Pharmaceutical Services has a fifty-two week low of $77.97 and a fifty-two week high of $103.36. The stock has a market cap of $6,164.51, a PE ratio of 29.97, a price-to-earnings-growth ratio of 2.13 and a beta of 1.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.89 and a current ratio of 2.66.
West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, February 15th. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. West Pharmaceutical Services had a return on equity of 14.68% and a net margin of 9.42%. The business had revenue of $415.60 million for the quarter, compared to analyst estimates of $416.90 million. During the same quarter in the previous year, the firm earned $0.54 earnings per share. The company’s revenue was up 8.7% on a year-over-year basis. sell-side analysts predict that West Pharmaceutical Services will post 2.85 EPS for the current year.
West Pharmaceutical Services announced that its Board of Directors has approved a share buyback plan on Thursday, February 15th that permits the company to repurchase 800,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.
A number of hedge funds and other institutional investors have recently modified their holdings of WST. Alliancebernstein L.P. boosted its position in West Pharmaceutical Services by 75.8% in the fourth quarter. Alliancebernstein L.P. now owns 2,042,166 shares of the medical instruments supplier’s stock valued at $201,500,000 after buying an additional 880,636 shares during the last quarter. TCW Group Inc. boosted its position in West Pharmaceutical Services by 127.0% in the fourth quarter. TCW Group Inc. now owns 715,727 shares of the medical instruments supplier’s stock valued at $70,621,000 after buying an additional 400,459 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new stake in West Pharmaceutical Services in the fourth quarter valued at approximately $39,036,000. William Blair Investment Management LLC boosted its position in West Pharmaceutical Services by 43.2% in the fourth quarter. William Blair Investment Management LLC now owns 1,272,407 shares of the medical instruments supplier’s stock valued at $125,548,000 after buying an additional 383,646 shares during the last quarter. Finally, BlackRock Inc. boosted its position in West Pharmaceutical Services by 5.8% in the fourth quarter. BlackRock Inc. now owns 6,230,224 shares of the medical instruments supplier’s stock valued at $614,734,000 after buying an additional 341,999 shares during the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/09/west-pharmaceutical-services-wst-rating-lowered-to-sell-at-valuengine.html.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.